Food allergy yardstick: Where does omalizumab fit?

Aikaterini Anagnostou, Marcus Shaker, Brian P Vickery, Julie Wang, Matthew Greenhawt

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2025;134(1):110-121

PMID: 39182580

Full Text on Elsevier Science View on PubMed

Abstract

Food allergy management has greatly evolved in the last several years, moving from passive approaches, such as strict food allergen avoidance, to more active treatments, including regulatory approval of the first specifically indicated immunotherapy product (for peanut) in 2020. In 2024, a second therapy, omalizumab, received regulatory approval for the treatment of 1 or more IgE-mediated food allergies, providing clinicians with multiple treatment options to offer patients and families. With this expanded armamentarium of food allergy treatment options, the practicing clinician requires detailed knowledge of benefits and risks of omalizumab, how omalizumab fits into the management landscape, and how to use shared decision-making to optimize therapy. This yardstick aims to provide the clinician with a review of data leading to omalizumab's food allergy indication and an evidence-based expert opinion approach regarding on how best to use this and other therapies available to optimize patient management.

Address: Department of Allergy and Immunology, Texas Children's Hospital, Houston, Texas. Electronic address: [email protected].; Division of Allergy and Immunology, Children's Hospital Colorado, School of Medicine, University of Colorado, Aurora, Colorado.; Section of Allergy and Clinical Immunology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire; Division of Allergy and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.; Division of Allergy and Immunology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia.; Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York.

DOI: 10.1016/j.anai.2024.07.034

Link outs

Free resources

Medical:

https://medlineplus.gov/foodallergy.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Omalizumab, Humans, Food Hypersensitivity, Anti-Allergic Agents, Immunoglobulin E, Allergens, Desensitization, Immunologic